We are delighted to provide deeper insight into a few of the cutting-edge scientific areas in Interventional Cardiology within Boston Scientific with the release of the latest edition of the Clinical Spotlight. As your peers, it is our pleasure to share the scientific story behind our robust portfolio providing you with the most current product and data news. This edition concentrates on an array of topics: recent data from the PLATINUMTM Diversity Trial, an overview of the benefits and features of the LOTUS EdgeTM TAVR/TAVI system, insight into the latest US clinical data on the WATCHMANTM device, recent preclinical and clinical SYNERGYTM data, and an overview of new and upcoming PCI technologies. Enjoy!
Craig A. Thompson, MD
Senior Vice President and Chief Medical Officer
Keith D. Dawkins, MD
Executive Vice President and Global Chief Medical Officer
Primary Endpoint of the PLATINUM Diversity Trial Presented at TCT 2016
Dr. Juan Granada discusses the importance of studying under-represented patient populations with co-principal investigator Dr. Wayne Batchelor.
The WATCHMAN™ Experience in Perspective
Read the perspectives of Dr. Reddy and Dr. Holmes on the recent WATCHMAN™ Post-FDA Approval and initial US clinical experience, and access a summary of Boston Scientific’s training resources.
SYNERGY: Optimal Healing and Safety
View preclinical and clinical data demonstrating evidence of optimal healing with the SYNERGY stent, learn about the recent FDA approval of SYNERGY for diabetic patients, and view the most recent SYNERGY clinical data presentations.
PCI Technology Report
Hear experts address new and upcoming PCI Technologies
Watch CMO Craig Thompson, Tim Girton, Boston Scientific’s VP of IC R&D, and Dr. Colm Hanratty, Chief of Clinical Cardiology at Belfast Hospital Trust discuss various new PCI technologies and view Professor de la Torre Hernandez’s study comparing BVS and SYNERGY in terms of clinical resource utilization.